Fennec Pharmaceuticals

Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Fennec Pharmaceuticals reports Q1 loss, sees growth in new therapies

Fennec Pharmaceuticals' Q1 2023 earnings call highlighted a mix of financial results, market strategies, and analyst inquiries. Despite challenges in achieving profitability, the company showcased strengths in product launches and market acceptance. Opportunities for growth through expanded adoption, market strategies, and R&D investments were discussed.

Fennec Pharmaceuticals reports robust revenue growth and strategic milestones in Q2 2023

Fennec Pharmaceuticals demonstrated strong revenue growth and key regulatory milestones in Q2 2023, positioning the company for future success.
While facing financial challenges and operational inquiries, Fennec's strategic focus on commercial expansion and patient support programs remains a key strength.
With a solid cash position and experienced leadership, Fennec is well-positioned to capitalize on market opportunities and drive further growth in the oncology sector.

Fennec Pharmaceuticals excels in Q3 with PEDMARK growth strategies

Fennec Pharmaceuticals demonstrated robust financial performance and strategic market positioning in Q3 2023, leveraging the successful launch of PEDMARK in the U.S. and plans for European expansion.
While facing challenges in metrics tracking, manufacturing transitions, and pipeline prioritization, the company remains focused on maximizing PEDMARK's market potential and competitive edge.
Opportunities lie in expanding market presence in Europe, negotiating favorable pricing strategies, and solidifying PEDMARK's position as a key therapy alongside cisplatin.

Fennec Pharmaceuticals excels in Q4 2023, secures strategic partnerships

Fennec Pharmaceuticals delivered strong financial results and strategic advancements in Q4 2023, positioning the company for growth.
While facing challenges in increased expenses and access barriers, Fennec's focus on pediatric oncology and strategic partnerships offer promising opportunities.
With a solid financial foundation and market endorsements, Fennec is well-positioned to capitalize on its growth potential and expand its market presence.

Fennec Pharmaceuticals reports solid Q1 performance amidst market challenges

Fennec Pharmaceuticals navigated challenges in Q1 2024 while maintaining strong financial performance and strategic advancements. The company's focus on resolving issues, expanding market reach, and optimizing sales strategies positions it for future success.

Fennec Pharmaceuticals reports solid Q2 performance, eyes market expansion

Fennec Pharmaceuticals' Q2 2024 performance reflects progress in PEDMARK's commercialization and market access.
While facing challenges in specific business segments, the company's strong financial position and strategic partnerships are notable strengths.
Opportunities lie in targeted market expansion and clear communication of growth strategies to investors.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fennec Pharmaceuticals Inc. ("Fennec" or the "Company") (NASDAQ: FENC). Investors who purchased Fennec shares are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/fenc. The investigation concerns whether Fennec and certain of its officers and/or directors have violated federal secu

Bronstein, Gewirtz & Grossman, LLC Notifies Fennec Pharmaceuticals Inc. (FENC) Investors of Investigation

San Diego, California--(Newsfile Corp. - February 10, 2022) - Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Fennec Pharmaceuticals Inc. ("Fennec" or the "Company") (NASDAQ: FENC) who purchased Fennec common stock between May 28, 2021 and November 26, 2021, both dates inclusive (the "Class Period"). To serve as lead plaintiff in this class action, you must move the Court no later than April...

(FENC) NEWS: Did you Suffer a Substantial Loss? Contact Johnson Fistel About Leading Fennec Pharmaceuticals Class Action Lawsuit

NEW YORK, Dec. 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fennec Pharmaceuticals Inc. ("Fennec" or the "Company") (NASDAQ: FENC). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fennec Pharmaceuticals Inc. - FENC

Fennec (FENC) suffers a setback again with a CRL for its new drug application (NDA) for Pedmark. Shares are down in pre-market trading.

Fennec (FENC) Gets CRL From FDA for Pedmark, Stock Down

The stock price of Fennec Pharmaceuticals Inc (NASDAQ: FENC) fell by over 8% during intraday trading today. This is why it happened.

Fennec Pharmaceuticals (FENC) Stock: Why The Price Fell Today

RESEARCH TRIANGLE PARK, N.C., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, today announced that it received a Complete Response Letter (CRL) on November 29, 2021 from the U.S. Food and Drug Administration (FDA), after the PDUFA target action date of November 27, 2021, regarding its New Drug Application (NDA) for PEDMARK™ (a unique formulation of sodium thiosulfate), for intravenous administration for the prevention of ototoxicity associated with cisplatin chemotherapy in pediatric patients ≥ 1 month to 18 years of age with localized, non-metastatic, solid tumors.

Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors

Fennec Pharmaceuticals Inc (NASDAQ: FENC) said it expects to receive a Complete Response Letter (CRL) from the FDA regarding its marketing application for Pedmark. Related Link:   Fennec Pharma Stock Is Trading Higher As Pedmark Is Under FDA Review For Chemo-Induced Toxicity.

Fennec Pharma Stock Plunges On Expected FDA CRL For Pedmark For Chemo-Induced Hearing Issues

The stock price of Fennec Pharmaceuticals Inc (NASDAQ: FENC) fell by over 35% pre-market today. This is why it happened.

Fennec Pharmaceuticals (FENC) Stock: Why The Price Is Dropping Today

FDA Pre-Approval Inspection Identified Deficiencies with the Facility of the Drug Product Manufacturer, Which Require Resolution Prior to PEDMARK Approval FDA Pre-Approval Inspection Identified Deficiencies with the Facility of the Drug Product Manufacturer, Which Require Resolution Prior to PEDMARK Approval

Fennec Pharmaceuticals Expects to Receive Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors

~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~

Fennec Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update

Fennec has a PDUFA date upcoming on Nov. 27 for its sodium thiosulfate formulation to treat hearing loss in children undergoing platinum-based chemotherapy. The company has been working on bringing Pedmark to market for some time - its NDA was rejected last year by the FDA owing to manufacturing issues.

Fennec Pharmaceuticals: Will Pedmark Make It To Market At Second Time Of Asking?

Apyx Medical Corp

Safe Bulkers

VirTra

SB, VTSI, FENC and APYX qualified the screen for breakout stocks for today.

4 Breakout Stocks for Impressive Returns

Adherex Technologies Inc. (FENC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Here's Why "Trend" Investors Would Love Betting on Adherex Technologies Inc. (FENC)

If you are looking for stocks that are well positioned to maintain their recent uptrend, Adherex Technologies Inc. (FENC) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Here's Why Momentum in Adherex Technologies Inc. (FENC) Should Keep going

Fennec Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update

The CRL manufacturing issue has been resolved and the PEDMARK NDA has been accepted. The wait has been very long, but a PDUFA action date of November 27 has been set, and we think this will be a meaningful catalyst.

Fennec Pharmaceuticals: The PEDMARK NDA Has Been Accepted, We Remain Bullish On The November PDUFA Catalyst

RESEARCH TRIANGLE PARK, N.C., June 24, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients with localized, non-metastatic solid tumors, today announced an amendment to its existing senior debt facility with the Life Sciences Group at Bridge Bank increasing the size of the facility from $18 million to $20 million.

Fennec Pharmaceuticals Announces Amendment to Increase Existing Senior Debt Facility

The FDA has accepted for review Fennec Pharmaceuticals Inc's (NASDAQ: FENC) resubmitted marketing application seeking approval for Pedmark (formulated sodium thiosulfate) to prevent ototoxicity induced by cisplatin chemotherapy. The application covers patients one month to < 18 years of age with localized, non-metastatic, solid tumors.

Fennec Pharma Stock Is Trading Higher As Pedmark Is Under FDA Review For Chemo-Induced Toxicity

﻿~ Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~﻿

Fennec Pharmaceuticals Announces FDA Acceptance of New Drug Application Resubmission for PEDMARK™

Fennec Pharmaceuticals Inc (NASDAQ: FENC) has resubmitted its marketing application to the FDA seeking approval for Pedmark (formulated sodium thiosulfate) for the prevention of ototoxicity (toxic to the ear) induced by cisplatin chemotherapy in patients one month, to less than 18 years, with localized, non-metastatic, solid tumors. The resubmission follows receipt of final minutes from a Type A meeting with the FDA.

Fennec Pharma Refiles Pedmark US Application For Cisplatin-Induced Ototoxicity In Pediatric Patients

AMC Entertainment

Iterum Therapeutics Plc

Mannatech

Vertex Energy

Here is an overview of 5 of the top stock gainers for May 28 during pre-market and why the stock prices moved. The post 5 Pre-Market Stock Gainers For May 28: VTNR, ITRM, MTEX, AMC, FENC appeared first on Pulse 2.0.

5 Pre-Market Stock Gainers For May 28: VTNR, ITRM, MTEX, AMC, FENC

~ Fennec Remains on Track to Finalize and Resubmit the New Drug Application for PEDMARK™ to the U.S. Food and Drug Administration in the Second Quarter of 2021 ~

Fennec Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update

~ Fennec is Working Closely with its Third-Party Drug Product Manufacturer to Finalize the New Drug Application (NDA) Resubmission for PEDMARK™ ~

Fennec Announces Fiscal Year 2020 Financial Results and Provides Business Update

~ The Company Continues to Work with the FDA and Its Third-Party Drug Product Manufacturer to Fully Address CRL and Prepare NDA Resubmission for PEDMARK™  ~

Fennec Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update

New York, New York--(Newsfile Corp. - November 2, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) alleging that the Company violated federal securities laws.Class Period: February 11, 2020 and August 10, 2020Lead Plaintiff Deadline: November 2, 2020Learn more about your recoverable losses in FENC:

FENC ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 2, 2020 in the Class Action Filed on Behalf of Fennec Pharmaceuticals Inc. Limited Shareholders

News for Fennec Pharmaceuticals Stock (FENC)